Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock. The Company intends to fund any share repurchases with available cash.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.